0000899243-20-009607.txt : 20200326 0000899243-20-009607.hdr.sgml : 20200326 20200326210141 ACCESSION NUMBER: 0000899243-20-009607 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200324 FILED AS OF DATE: 20200326 DATE AS OF CHANGE: 20200326 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TOMBESI PAOLO CENTRAL INDEX KEY: 0001707648 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 20747675 MAIL ADDRESS: STREET 1: 10 FINDERNE AVENUE STREET 2: BUILDING 10 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-24 0 0001571498 Epizyme, Inc. EPZM 0001707648 TOMBESI PAOLO C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Common Stock, par value $0.0001 2020-03-24 4 A 0 1690 A 16680 D Common Stock, par value $0.0001 2020-03-25 4 S 0 1243 15.28 D 15437 D Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. /s/ John Weidenbruch, attorney-in-fact 2020-03-26